

Colonic tubular adenoma with clear cell change

Ádám Ferenczi¹, Dr. Levente Kuthi Ph.D.^{2,3}, Dr. István Sejben Ph.D.⁴, Dr. Anita Sejben Ph.D.¹

¹Department of Pathology, University of Szeged, Szeged, Hungary
²Department of Surgical and Molecular Pathology, Center of Tumor Pathology, National Institute of Oncology, Budapest, Hungary
³Department of Pathology and Experimental Cancer Research Institute, Semmelweis University,, Budapest, Hungary
⁴Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary



Introduction: Colorectal tubular adenomas displaying clear cell change are rare entities, with unknown clinical relevance, prognosis, immunohistochemical, and molecular features. So far, solely 22 cases have been reported in the literature, and whole exome sequencing (WES) has never been carried out before.

Case report: Hereby we report a case of a 43-year-old female patient, who underwent colonoscopy due to hematochezia. During the examination, a rectosigmoid polyp was found. Histologically, conventional dysplasia was visible with scattered areas displaying clear cell change. Immunohistochemical examination was performed, and Glypican 3, SALL4, AFP, and CD10 were negative. WES (FASTQ Generation 1.0.0.) was carried out and revealed high tumour mutation burden, and 7 pathogenic mutations, including *TP53*, *APC*, *FGFR4*, *EHBP1*, *IL4R*, *TYR*, and *ACTN3*.

Discussion: Clear cell change may only be present in less than 0.1% of adenomas, according to the current World Health Organisation’s (WHO) Digestive Classification of digestive system tumours. Aetiology is not well understood, additionally, few authors suggest autolysis or fixation problems. Our WES resulted in newly found pathogenic mutations, and high mutation burden, proving the lesion’s neoplastic origin, and disproving the earlier assumptions regarding its potentially iatrogenic or autolytic origin. Hitherto, neither special stainings, nor immunohistochemical markers proved to be useful in the diagnostic process. From a differential diagnostic perspective, enteroblastic differentiation, primary and secondary clear cell adenocarcinoma has to be excluded in each case.




Figure 1 Microscopic finding of the rectosigmoid polyp.
A: Pedunculated polyp composed of tubular structures (HE, 1x).
B: Low-grade conventional dysplasia and clear cell change was visible in a patchy manner (HE, 10x).
C: Clear cells were visible with vacuolated cytoplasm, and eventually, signet ring cell morphology (HE, 15x).
D: Mutant phenotype was observed with p53 (p53, 10x).

Gene	Variant allele frequency	ClinVar significance	Coding impact
<i>TP53</i>	8.4%	Pathogenic	Missense
<i>APC</i>	17.2%	Pathogenic	Nonsense
<i>FGFR4</i>	44.3%	Pathogenic	Missense
<i>EHBP1</i>	27.5%	Pathogenic	Splice site variant
<i>IL4R</i>	48.8%	Pathogenic	Missense
<i>TYR</i>	47.6%	Pathogenic	Missense
<i>ACTN3</i>	43.4%	Pathogenic	Nonsense
<i>PDX1</i>	42.3%	Likely	Missense

Table 1 Summary of pathogenic and likely pathogenic mutations found in our case
(ACTN3 - Alpha actin 3; APC - Adenomatous polyposis coli; EHBP1 - EH domain binding protein 1; FGFR4 - Fibroblast growth factor receptor 1; IL4R - Interleukin 4 receptor; PDX1 - Pancreatic and duodenal homeobox 1; TP53 - Tumour protein p53; TYR - Tyrosinase)

This project was supported by the New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. (ÚNKP-23-4-SZTE-389) and the University of Szeged, Faculty of Medicine Research Fund-Hetényi Géza Grant (IV-134-62-1/2024.SZAOK).

**VLADIMIR TOTÓVIĆ-STIFTUNG
ZUR FÖRDERUNG DER PATHOLOGIE
IM STIFTERVERBAND**

POSTER-PRIZE 2024

The Vladimir Totović-Foundation awards its Poster Prize 2024 for the
best poster presentation
to

ÁDÁM FERENCZI

for his work

Colonic tubular adenoma with clear cell change - case report with whole exome sequencing

at the 7th Pannonia Congress of Pathology, held from March 7 to 9, 2024,
in Vienna, Austria.

Vienna, March 2024


Prof. Dr. Sigurd Lax
Board member of the Vladimir Totović-Foundation
and member of the organizing committee
of the 7th Pannonia Congress of Pathology



STIFTERVERBAND

PANNONIA CONGRESS OF PATHOLOGY

7th



SPRING MEETING 2024

MARCH 7TH – 9TH | TECHGATE VIENNA, DONAU CITY WIEN



ÖSTERREICHISCHE GESELLSCHAFT FÜR
KLINISCHE PATHOLOGIE UND MOLEKULARPATHOLOGIE
ÖSTERREICHISCHE ABTEILUNG DER
INTERNATIONALEN AKADEMIE FÜR PATHOLOGIE



Erster zugelassener bispezifischer
Antikörper im NSCLC²

Einziges zielgerichtete Therapie für
NSCLC mit aktivierenden
EGFR **EXON20** Insertionsmutationen^{*1,2}

ZIELGENAU.²

EFFEKTIV.^{#3}

Fast
2
Jahre Gesamtüberleben³

40%
Gesamtansprechrate³

Nur
3%
Abbruchrate²

1. Remon, J et al. Cancer Treatment Reviews. 90 (2020). 2. Fachinformation RYBREVENT®, Stand 12/2021. 3. Park K et al. J Clin Oncol 2021; 39:3391-3402.

* Monotherapie nach platinbasierter Therapie²

Medianes Gesamtüberleben (OS, sekundärer Endpunkt): 22,8 Monate (95%-KI: 14,6-nicht abschätzbar; Datenschnitt Okt. 2020); Medianes progressionsfreies Überleben (PFS, sekundärer Endpunkt): 8,3 Monate (gemäß BICR; 95%-KI: 6,5-10,9; Datenschnitt Okt. 2020); N = 81³; Gesamtansprechrate (ORR; Ansprechen gemäß RECIST v1.1): 40% (95%-KI: 29-51, blinded independent central review, BICR; initiale Ergebnisse mit Datenschnitt Okt. 2020); 43% gemäß BICR; 95%-KI: 34-53; aktuellster Datenschnitt März 2021³

³ n=380; Datenschnitt vom März 2021

Bezeichnung des Arzneimittels: Rybrent 350 mg Konzentrat zur Herstellung einer Infusionslösung. **Qualitative und quantitative Zusammensetzung:** Ein ml des Konzentrats zur Herstellung einer Infusionslösung enthält 50 mg Amivantamab. Eine 7 ml-Durchstechflasche enthält 350 mg Amivantamab. Amivantamab ist ein vollhumaner, auf Immunglobulin G1 (IgG1) basierender bispezifischer Antikörper, der gegen den epidermalen Wachstumsfaktor-Rezeptor (epidermal growth factor, EGFR) und den mesenchymal-epithelialen Transitionsfaktor (MET) gerichtet ist und mittels rekombinanter DNA-Technologie aus einer Säugtierzelllinie (Chinesische Hamster Ovary [CHO]) hergestellt wird. Sonstige Bestandteile: Natriumedetat (Ph. Eur.), Histidin, Histidinhydrochlorid-Monohydrat, Methionin, Polysorbat 80 (E433), Saccharose, Wasser für Injektionszwecke. **Anwendungsgebiete:** Rybrent als Monotherapie ist indiziert zur Behandlung erwachsener Patienten mit fortgeschrittenem, nicht-kleinzelligem Lungenkarzinom (non small cell lung cancer, NSCLC) und aktivierenden Exon 20-Insertionsmutationen des epidermalen Wachstumsfaktor-Rezeptors (EGFR) nach Versagen einer platinbasierten Therapie. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. **Inhaber der Zulassung:** Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgien. **Vertrieb für Österreich:** JANSSEN-CILAG Pharma GmbH, Vorgartenstraße 206B, A-1020 Wien. **Verschreibungspflicht/Apothekenpflicht:** Rezept- und apothekenpflichtig. ATC-Code: L01FX18. Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Schwangerschaft und Stillzeit sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Es ist daher wichtig, jeden Verdachtsfall einer Nebenwirkung in Bezug auf RYBREVENT® zu melden.
AT_CP-355020_20221104



Janssen-Cilag Pharma GmbH

www.rybrent.at

Janssen Oncology
PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

AT_CP-402863_20230726

Invitation

Dear colleagues and friends,

with great pleasure I extend a warm welcome to you all to the 7th Pannonia Congress of Pathology, taking place in the vibrant city of Vienna from March 7th to 9th, 2024.

Over the past fourteen years, the Pannonia Congress of Pathology has evolved into an important event for pathologists across the Central European region. From its beginnings in Graz, Austria, to this gathering in Vienna, our congress has consistently attracted esteemed speakers and participants from both within and outside the Pannonia region.

This year's congress promises to be particularly enriching, with a diverse program covering interesting topics ranging from lung pathology and gastrointestinal pathology to skin, kidney, and gynecological pathology. Continuing the tradition of the Austrian Society of Pathology /IAP Austria's Spring meetings, Friday morning sessions will be dedicated to addressing preanalytical issues, accreditation, digitalization in pathology, and teaching, catering specifically to our esteemed biomedical analysts. Furthermore, there will be an active poster session, with attractive prizes provided by the Vladimir Totović Foundation and the Austrian Society of Pathology/IAP Austria.

We extend our gratitude to all our sponsors, whose generous support has made this meeting possible.

As you gather in Vienna, you will not only engage in stimulating scientific discussions but also immerse yourselves in the rich cultural tapestry of this historic city. From its architectural splendor to its culinary delights and renowned hospitality, Vienna offers a perfect background for our congress.

I am confident that the 7th Pannonia Congress of Pathology will serve as a pleasant reunion of old friends, fostering collaboration, innovation, and friendships among pathologists from diverse backgrounds.

Welcome to Vienna, and welcome to the 7th Pannonia Congress of Pathology for what promises to be a memorable and rewarding experience.

Warm regards,

Luka Brčić

On behalf of the Local Organizing Committee

Programme Overview

THURSDAY 7th March 2024

from 7:00	Registration
08:00 – 10:00	Lung Pathology
10:00 – 10:30	Coffee Break
10:30 – 12:00	Lung Pathology
12:00 – 12:30	Industry Symposia Roche
12:30 – 13:00	Industry Symposia Astellas
13:00 – 13:30	Break
13:30 – 14:45	Gastrointestinal Pathology Practical Update on Selected Topics from the Upper Gastrointestinal Tract
14:45 – 15:30	Gastrointestinal Pathology Challenging Cases from Pannonian Countries
15:30 – 16:00	Coffee Break
16:00 – 17:30	Gastrointestinal Pathology
17:30 – 18:30	Gastrointestinal Pathology Challenging Cases from Pannonian Countries
18:30 – 18:45	Business Meeting
19:00	Get together

FRIDAY 8th March 2024

from 7:30	Registration
08:30 – 10:00	Preanalytics / Accreditation
10:00 – 10:30	Coffee Break
10:30 – 11:00	Industry Symposia Bristol Myers Squibb
11:00 – 12:30	Digital Pathology
12:30 – 13:30	Lunch Break / Poster Session
13:30 – 14:30	Digital Pathology
14:30 – 15:15	Keynote / special lecture
15:15 – 15:30	Henry Rappaport Grant
15:30 – 16:00	Coffee Break
16:00 – 18:30	Skin I / Renal Pathology (non-neoplastic disorders affecting skin and kidney)
19:00	Congress Dinner / Poster Prize Ceremony

Programme Overview

SATURDAY 9th March 2024

08:00 – 09:00	Patho-Run
09:30 – 11:00	Gyn
11:00 – 11:30	Coffee Break
11:30 – 12:00	Industry Symposia Astra Zeneca
12:00 – 12:30	Gyn
12:30 – 13:30	Lunch Break
13:30 – 15:30	Gyn Case Seminar

General Information

Organizer

Austrian Society of Pathology / Austrian Division of the International Academy of Pathology (OEGPath/IAP Austria)

Represented by:

Alexander Nader

Department of Pathology and Microbiology

Hanusch-Krankenhaus, Heinrich-Collin-Straße 30, 1140 Vienna

Local Organizing Committee

Luka Brčić (AT), Renate Kain (AT), Sigurd Lax (AT), Alexander Nader (AT)

Scientific Committee

Luka Brčić (AT), Pavel Dundr (CZ), Tibor Glasz (HUN), Pavol Janega (SVK), Jera Jeruc (SLO), Renate Kain (AT), Janina Kulka (HUN), Cord Langner (AT), Sigurd Lax (AT), Alexander Nader (AT), Helmuth Popper (AT), Sven Seiwerth (CRO), Metka Volavšek (SLO)

Congress Venue

TechGate Vienna

Donau-City-Straße 1, 1220 Wien

Congress Language

English

Congress Office

MAW – Congress office OEGPath

Verena Schachenhofer

Jasmin Amon

Freyung 6, 1010 Wien

Tel.: +43 1 536 63-26 or -81, Fax: +43 1 531 16-61

E-Mail: oegpath@media.co.at

Exhibition Management and Sponsoring

MAW – International Exhibitions and Advertising

Medizinische Ausstellungs- und Werbegesellschaft

Freyung 6/3, 1010 Wien

Tel.: +43 1 536 63-26 or -81, Fax: +43 1 535 60 16

E-Mail: oegpath@media.co.at

General Information

Information for Speakers

Speakers are requested to submit their presentations at latest 2 hours before their lectures on an USB-Stick as MS Powerpoint.

DFP-Credits



This event has been accredited for the advanced diploma education program (Diplom-Fortbildungs-Programm DFP) of the Austrian Medical Chamber. 10 points will be granted for Thursday, March 7th, 10 points for Friday, March 8th and 6 points for Saturday, March 9th.

CPD-Credits

The event is assessed by biomed austria – Österreichischer Berufsverband der Biomedizinischen AnalytikerInnen with 10 CPD points for Thursday, March 7th, 10 CPD points for Friday, March 8th and 9 CPD points for Saturday, March 9th.



Registration

online under <https://tagung.oegpath.at/>

Registration Fees

	Type	Regular Fee	Day Pass
Member*	Medical Doctor	€ 300,-	€ 180,-
	Medical Doctor Trainee or on Maternity Leave**	€ 100,-	€ 70,-
	Biomedical Analysts	€ 100,-	€ 70,-
Non-Member	Medical Doctor	€ 600,-	€ 400,-
	Medical Doctor Trainee or on Maternity Leave**	€ 200,-	€ 150,-
	Biomedical Analysts	€ 200,-	€ 150,-

Students**

Free

Industry Staff member (of non-sponsoring company)

€ 540,-

€ 600,-

Social Dinner	Medical Doctor/Regular Fee		€ 50,-
	Medical Doctor Trainee or on Maternity Leave		€ 25,-
	Biomedical Analysts		€ 25,-
	Students		€ 25,-

* Please submit a written proof of your membership at your local society of pathology or the European Society of Pathology to oegpath@media.co.at

** Please submit a written proof of your trainee/student status to oegpath@media.co.at

General Information

Payment

Payment via bank transfer not later than March 1st to the following bank account:

Recipient: OEGPath

Bank: Erste Bank

IBAN: AT12 2011 1281 3342 8704

BIC: GIBAATWW

Reference: Last name, first name + PATHOLOGIE24

Payment by credit card

After completing the online registration form you will be forwarded directly to the payment page for credit card payment.

Cancellation and Refund

Notice of cancellation must be made in writing by e-mail to office@oegpath.at.

For written cancellations up to 2 weeks prior to the congress date 100% of the registration fee will be refunded.

After this deadline, no refunds can be granted.

Certificate of Attendance

You will receive the Certificate of Attendance daily on site at the registration desk. Please make sure to pick it up every morning.

Registration Desk Opening Hours

Thursday, March 7th 7:00 am – 6:00 pm

Friday, March 8th 7:30 am – 6:00 pm

Saturday, March 9th 8:00 am – 3:00 pm

WIFI

TechGate Vienna

Password: The Stage

Please note that photos for documentary reasons will be made during the congress.

Get-together

Thursday, March 7th 2024, 7:00 pm at Sky Stage
(19th floor of the congress venue TechGate)

Society Dinner

Friday, March 8th 2024, 7:00 pm at Sky Stage
(19th floor of the congress venue TechGate)

13th Patho-Run

Saturday, March 9th 2024, 8:00 am

Start and Goal: TechGate Vienna **Distance:** approx. 5 km

All participants receive a Patho-Run T-Shirt. Please register online and indicate your T-shirt size if you want to join the Patho-Run.

Scientific Programme

THURSDAY 7th March 2024

from 07:00 Registration

08:00 – 10:00 Lung Pathology

*Chairs: Helmut Popper (Graz, Austria),
Lukáš Plank (Martin, Slovakia)*

08:00 – 08:24 Sample management in the era of broad
molecular testing of NSCLC

Lovorka Batelja Vuletić (Zagreb, Croatia)

08:24 – 08:48 Upcoming predictive markers for targeted
therapy of NSCLC

Reinhard Büttner (Cologne, Germany)

08:48 – 09:12 Discordance of ALK rearrangement and
ALK protein expression in NSCLC: possible contributing
factors and the implication for clinical practice

Katarína Tobiášová (Martin, Slovakia)

09:12 – 09:36 Neoadjuvant therapy from pathologists' perspective

Dagmar Krenbek (Vienna, Austria)

09:36 – 10:00 Are NET in lung really different from all others?

János Fillinger (Budapest, Hungary)

10:00 – 10:30 Coffee Break

10:30 – 12:00 Lung Pathology

*Chairs: Helmut Popper (Graz, Austria),
Lukáš Plank (Martin, Slovakia)*

10:30 – 10:48 What to do with eosinophils in lung?

Luka Brčić (Graz, Austria)

10:48 – 11:06 Pulmonary manifestations of tuberous
sclerosis complex

András Khoór (Hungary/USA)

11:06 – 11:24 Granulomas, same but so different.

Mile Kovačević (Golnik, Slovenia)

11:24 – 11:42 When is IPF actually an HP?

Radoslav Matěj (Prague, Czech Republic)

11:42 – 12:00 Placental transmogrification of the lung

Tomáš Krajčovič (Bratislava, Slovakia)

Willkommen in der Therapielandschaft des Magenkarzinoms




Neue Biomarker eröffnen zusätzliche Möglichkeiten der Behandlung von Tumoren des Magens sowie des gastroösophagealen Übergangs.^{1,2}

CLDN18.2=Claudin18.2; **FGFR2b**=fibroblast growth factor receptor 2b; **HER2**=human epidermal growth factor receptor 2; **MSI**=microsatellite instability; **PD-L1**=programmed death-ligand 1.

Referenzen: 1. Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. *Br J Cancer* 2019;121(3):257-63. 2. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. *World J Gastroenterol* 2018;24(26):2818-32.

Astellas Pharma Ges.m.b.H. Donau-City-Straße 7, 1220 Wien, www.astellas.at;
E-Mail: office.at@astellas.com

MAT-AT-NON-2023-00010 Erstellt Juli 2023



Scientific Programme

THURSDAY 7th March 2024

12:00 – 12:30 Industry Symposia Roche



Claudin 18.2 – A new biomarker for routine pathology

Katja Schmitz (Zams, Austria)

12:30 – 13:00 Industry Symposia Astellas



Claudin 18.2 as a new target and future treatment strategies for mG/GEJ adenocarcinoma

Aysegül İlhan-Mutlu (Vienna, Austria)

13:00 – 13:30 Break

13:30 – 14:45 Gastrointestinal Pathology

Practical Update on Selected Topics from the Upper Gastrointestinal Tract

Chairs: Jera Jeruc (Ljubljana, Slovenia),

Martin Klimpfinger (Vienna, Austria)

13:30 – 13:55 Soft tissue pathology of the upper gastrointestinal tract: It's not always a GIST

Bernadette Liegl-Atzwanger (Graz, Austria)

13:55 – 14:20 Chronic oesophageal reflux and Barrett oesophagus (including diagnosis of dysplasia)

Béla Vasas (Szeged, Hungary)

14:20 – 14:45 Precursors of squamous cell carcinoma

Nina Zidar (Ljubljana, Slovenia)

14:45 – 15:30 Gastrointestinal Pathology

Challenging Cases from Pannonian Countries

Chairs: Marian Svajdler (Bratislava, Slovakia),

Behrang Mozayani (Vienna, Austria)

14:45 – 15:00 Case 1

Anita Sejben (Szeged, Hungary)

15:00 – 15:15 Case 2

Friedrich Jakse (Vienna, Austria)

15:15 – 15:30 Case 3

Nika Kojc (Ljubljana, Slovenia)

15:30 – 16:00 Coffee Break

THURSDAY 7th March 2024

- 16:00 – 17:30 Gastrointestinal Pathology**
*Chairs: Marion Pollheimer (Graz, Austria),
Ondřej Daum (Plzeň, Czech Republic)*
- 16:00 – 16:30 HP-negative gastritis**
Zlatko Marušić (Zagreb, Croatia)
- 16:30 – 17:00 Gastric dysplasia and early gastric cancer
(including EMR and ESD)**
Kateřina Kamarádová (Hradec Králové, Czech Republic)
- 17:00 – 17:30 Oesophagitis not related to reflux disease**
Cord Langner (Graz, Austria)
- 17:30 – 18:30 Gastrointestinal Pathology
Challenging Cases from Pannonian Countries**
*Chairs: Metka Volavšek (Ljubljana, Slovenia)
Cord Langner (Graz, Austria)*
- 17.30 – 17.45 Case 4**
Polina Kalinina (Vienna, Austria)
- 17:45 – 18:00 Case 5**
Juraj Marcinek (Martin, Slovakia)
- 18:00 – 18:15 Case 6**
Sara Hrg (Zagreb, Croatia)
- 18:15 – 18:30 Case 7**
Magdaléna Daumová (Plzeň, Czech Republic)
- 18:30 – 18:45 Business Meeting**
- 19:00 Get together**

Scientific Programme

FRIDAY 8th March 2024

- 08:30 – 10:00 Preanalytics / Accreditation**
*Chairs: Renate Kain (Vienna, Austria),
Tibor Glasz (Budapest, Hungary)*
- 08:30 – 09:00** The importance of fixation for proper analysis in anatomic and molecular pathology
Kurt Zatloukal (Graz, Austria)
- 09:00 – 09:30** Preanalytical parameters and molecular analysis
Marija Milavić (Zagreb, Croatia)
- 09:30 – 10:00** Validation of immunohistochemistry and in situ hybridization for accreditation
Milena Öttl (Graz, Austria), Sigurd Lax (Graz, Austria)
- 10:00 – 10:30 Coffee Break**
- 10:30 – 11:00 Industry Symposia**  Bristol Myers Squibb™
Bristol Myers Squibb
Pathological challenges and clinical updates in NSCLC –
Pathologic complete response and rare mutations
Luka Brcic (Graz, Austria), Maximilian Hochmair (Wien, Austria)
- 11:00 – 12:30 Digital Pathology**
*Chairs: Jera Jeruc (Ljubljana, Slovenia),
Sven Seiwert (Zagreb, Croatia)*
- 11:00 – 11:30** Digitalisation matters
Michael HA Roehrl (Boston, USA)
- 11:30 – 12:00** Beyond Digital Pathology
Heimo Müller (Graz, Austria)
- 12:00 – 12:30** Quality matters!
David Brette (Leeds, UK)
- 12:30 – 13:30 Lunch Break / Poster Session**
- 13:30 – 14:30 Digital Pathology**
*Chairs: Jera Jeruc (Ljubljana, Slovenia),
Sven Seiwert (Zagreb, Croatia)*
- 13:30 – 14:00** Digital Pathology without Borders
*Birgit Ringelhan (Hungary),
Wolfgang Hulla (Wiener Neustadt, Austria)*
- 14:00 – 14:30** National program of digitalization of Pathology in Slovakia
Lukáš Plank (Martin, Slovakia)

FRIDAY 8th March 2024

- 14:30 – 15:15 Keynot/special lecture**
Chairs: Janina Kulka (Budapest, Hungary)
- 14:30 – 15:15 Pathology in Medical Curriculum in Pannonia Countries**
Aleš Ryška (Hradec Králové, Czech Republic)
- 15:15 – 15:30 Henry Rappaport Grant**
- 15:30 – 16:00 Coffee Break**
- 16:00 – 18:30 Skin I / Renal Pathology**
(non-neoplastic disorders affecting skin and kidney)
Chairs: Danica Ljubanović (Zagreb, Croatia)
András Kiss (Budapest, Hungary)
- 16:00 – 16:30 Clinical picture and skin pathology of Collagen disorders**
Mirna Bradamante (Zagreb, Croatia)
- 16:30 – 17:00 Pathology of collagen disorders in the kidney**
(Alprot spectrum disorders)
Danica Ljubanović (Zagreb, Croatia)
- 17:00 – 17:30 Clinical picture of multi-system disorders**
affecting the Skin and Kidney
Vladimír Tesař (Prague, Czech Republic)
- 17:30 – 18:00 Renal Pathology in multi-system disorders**
(Vasculitis and SLE)
Renate Kain (Vienna, Austria)
- 18:00 – 18:30 Pathology of Skin in multi-system disorders**
(Vasculitis and SLE)
Eva Sticova (Prague, Czech Republic)
- 19:00 Congress Dinner / Poster Prize Ceremony**

Scientific Programme

SATURDAY 9th March 2024

08:00 – 09:00 Patho-Run

09:30 – 11:00 **Gyn**

Chairs: Sigurd Lax (Graz, Austria)

Marina Kos (Zagreb, Croatia)

09:30 – 10:00 Molecular classification of endometrial carcinoma
Sigurd Lax (Graz, Austria)

10:00 – 10:30 Tubo-ovarian serous carcinoma
Kristýna Němejcová (Prague, Czech Republic)

10:30 – 11:00 Mucinous ovarian neoplasms: Differential diagnosis and molecular features
Pavel Dundr (Prague, Czech Republic)

11:00 – 11:30 **Coffee Break**

11:30 – 12:00 **Industry Symposia Astra Zeneca**

AstraZeneca 

Molecular testing in breast cancer –
current guidelines and future perspectives
Katja Schmitz (Zams, Austria)

12:00 – 12:30 The role of HPV testing in cervical screening programs in Eastern/Central Europe
Mario Poljak (Slovenia)

12:30 – 13:30 **Lunch Break / Industry Exhibition**

13:30 – 15:30 **Gyn Case Seminar**

Chairs: Lilla Madaras (Budapest, Hungary)

Snježana Frković-Grazio (Ljubljana, Slovenia)

Case Presentation by:

Ľudovít Danihel (Bratislava, Slovakia)

Snježana Frković-Grazio (Ljubljana, Slovenia)

Zuzana Hríbková (Bratislava, Slovakia)

Monica Stephany Kirigin (Zagreb, Croatia)

Marina Kos (Zagreb, Croatia)

Lilla Madaras (Budapest, Hungary)

Speakers

Bateljja Vuletić Lovorka

University of Zagreb, School of Medicine, Department of Pathology,
Zagreb, CROATIA

Bradamante Mirna

University of Zagreb, School of Medicine, University Department of
Dermatology and Venerology, Zagreb, CROATIA

Brić Luka

Medical University of Graz, Diagnostic and Research Institute of Pathology,
Graz, AUSTRIA

Brettle David

Leeds Teaching Hospital NHS Trust, Leeds, UNITED KINGDOM

Büttner Reinhard

University Hospital Cologne, Medical Faculty, Institute of Pathology,
Cologne, GERMANY

Danihel Ľudovít

Comenius University Bratislava, Institute of Pathology, Faculty of Medicine,
Bratislava, SLOVAKIA

Daum Ondřej

Charles University and Bioptical Laboratory, SIKL's Institute of Pathology,
Faculty of Medicine and Teaching Hospital Plzeň, CZECH REPUBLIC

Daumová Magdaléna

Charles University and Bioptical Laboratory, SIKL's Institute of Pathology,
Faculty of Medicine and Teaching Hospital Plzeň, CZECH REPUBLIC

Dundr Pavel

Charles University and General University Hospital Prague, First Faculty of
Medicine, Department of Pathology, Prague, CZECH REPUBLIC

Fillinger János

National Koranyi Institute of Pulmonology, Budapest, HUNGARY

Frković-Grazio Snježana

University Medical Centre Ljubljana, Division of Gynecology, Department of
Pathology, Ljubljana, SLOVENIA

Glasz Tibor

Semmelweis University, Department of Pathology, Budapest, HUNGARY

Hrg Sara

University Hospital Center Zagreb, Institute of Pathology and Cytology, Zagreb,
CROATIA

Hríbková Zuzana

Diagnostic centrum of Pathology Presov, Unilabs Slovensko, s.r.o., Presov,
SLOVAKIA

Hulla Wolfgang

Landeskrankenhaus Wiener Neustadt, Institute of Pathology, Wiener Neustadt,
AUSTRIA

Speakers

Jakse Friedrich

Medical University of Vienna, Department of Pathology, Vienna, AUSTRIA

Jeruc Jera

University of Ljubljana, Medical Faculty, Institute of Pathology, Ljubljana, SLOVENIA

Kain Renate

Medical University of Vienna, Department of Pathology, Vienna, AUSTRIA

Kalinina Polina

Medical University of Vienna, Department of Pathology, Vienna, AUSTRIA

Kamarádová Kateřina

Charles University, Medical Faculty, The Fingerland Department of Pathology, Hradec Králové, CZECH REPUBLIC

Khoór András

Mayo Clinic College of Medicine and Science, Department of Laboratory Medicine and Pathology, HUNGARY

Kirigin Monica Stephany

Medical School University of Zagreb, Institute of Pathology, Zagreb, CROATIA

Kiss András

Semmelweis University, 2nd Department of Pathology, Budapest, HUNGARY

Klimpfinger Martin

Labor für Zytologie und Histologie Dr. Ulm GmbH und Gastprofessor am Institut für Klinische Pathologie der Medizinischen Universität, Vienna, AUSTRIA

Kojc Nika

University of Ljubljana, Medical Faculty, Institute of Pathology, Ljubljana, SLOVENIA

Kos Marina

Medical School University of Zagreb, Institute of Pathology, Zagreb, CROATIA

Kovačević Mile

University Clinic Golnik, Laboratory for Cytology and Pathology, Golnik, SLOVENIA

Krajčovič Tomáš

Unilabs Slovakia Ltd., Diagnostic Center of Pathology, Bratislava, SLOVAKIA

Krenbek Dagmar

Klinik Floridsdorf, Institute of Pathology, Vienna, AUSTRIA

Kulka Janina

Semmelweis University, Pathology, Forensic and Insurance Medicine, Budapest, HUNGARY

Langner Cord

Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, AUSTRIA

Speakers

Lax Sigurd

LKH Graz II, Department of Pathology and Johannes Kepler University Linz, Graz, AUSTRIA

Liegl-Atzwanger Bernadette

Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, AUSTRIA

Ljubanović Danica

University of Zagreb, School of Medicine, Department of Pathology, Zagreb, CROATIA

Madaras Lilla

Semmelweis University, Forensic and Insurance Medicine, Department of Pathology, Budapest, HUNGARY

Marcinek Juraj

University in Martin, Jessenius Medical Faculty of Comenius, Martin, SLOVAKIA

Marušić Zlatko

University Hospital Centre Zagreb, Clinical Department of Pathology and Cytology, Zagreb, CROATIA

Matěj Radoslav

Charles University and Thomayer University Hospital, Third Faculty of Medicine, Department of Pathology and Molecular Medicine, Prague, CZECH REPUBLIC

Milavić Marija

University of Zagreb, School of Medicine, Department of Pathology, Zagreb, CROATIA

Mozayani Behrang

Medical University Vienna, Institute of Pathology, Vienna, AUSTRIA

Müller Heimo

Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, AUSTRIA

Němejcová Kristýna

Charles University and General University Hospital in Prague, First Faculty of Medicine, Institute of Pathology, Prague, CZECH REPUBLIC

Öttl Milena

LKH Graz II, Department of Pathology, Graz, AUSTRIA

Plank Lukáš

Jessenius Medical Faculty of Comenius University in Martin, Department of Pathology, Martin, SLOVAKIA

Poljak Mario

University of Ljubljana, Faculty of Medicine, Institute of Microbiology and Immunology, Ljubljana, SLOVENIA

Pollheimer Marion

Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, AUSTRIA

Speakers

Popper Helmut H.

Medical University of Graz, Diagnostic and Research Institute of Pathology,
Graz, AUSTRIA

Ringelhan Birgit

Sopron Medical Center, Elizabeth Teaching Hospital and Rehabilitation Institute,
Department of Pathology, Sopron, HUNGARY

Roehrl Michael H.A.

Harvard Medical School, Beth Israel Deaconess Medical Center, Department of
Pathology, Boston, UNITED STATES

Ryška Aleš

Charles University, Medial Faculty, The Fingerland Department of Pathology,
Hradec Králové, CZECH REPUBLIC

Seiwerth Sven

University of Zagreb, Department of Pathology, Zagreb, CROATIA

Sejben Anita

University of Szeged, Institute of Pathology, Szeged, HUNGARY

Sticova Eva

Teaching Hospital Kralovske Vinohrady, Charles University, 3rd Faculty of
Medicine, Prague, CZECH REPUBLIC

Švajdler Marian

Charles University and Bioptical Laboratory,
Faculty of Medicine and Teaching Hospital,
Sikl's Institute of Pathology, Bratislava / Plzeň, CZECH REPUBLIC

Tesař Vladimír

General University Hospital, Charles University, Department of Nephrology,
Prague, CZECH REPUBLIC

Tobiášová Katarína

Comenius University Jessenius Medical Faculty and University Hospital in
Martin, Department of Pathology, Martin, SLOVAKIA

Vasas Béla

University of Szeged, Institut of Pathology, Szeged, HUNGARY

Volavšek Metka

University of Ljubljana, SLOVENIA

Zatloukal Kurt

Medical University of Graz, Diagnostic and Research Institute of Pathology,
Graz, AUSTRIA

Zidar Nina

University of Ljubljana, Medical Faculty, Institute of Pathology,
Ljubljana, SLOVENIA

Poster 1: Implementation of ISO 9001: 2015 Standard in the Clinical Institute for Pathology and Cytology "Ljudevit Jurak" KBC SM

Mario Balta, Marina Blažević, Adriana Medur, Jelena Barać Žutelija, Monika Ulamec

Poster 2: A case of long lasting EBV-reactivation with dramatic turn

Rosa Brand, Ingrid Simonitsch-Klupp

Poster 3: Is There a Difference in the Results of FISH-Analysis in Multiple Myeloma between Samples of Isolated Plasma Cells and Bone Marrow Smears?

Magdalena Buči, Maja Vučetić, Suzana Hančić, Anita Škrtić

Poster 4: RANKL/OPG expression ratio in the dura mater tissue with biomineralization

Anastasiia Denysenko, Roman Moskalenko

Poster 5: Changes in breast cancer grade from biopsy to excision following surgery or primary chemotherapy

Adam Ferenczi, Gabor Cserni

Poster 6: Impact of prognostic subtyping of special types of triple-negative breast cancer on outcome and correlation with clinicopathological features

Claudia Grosse, Petar Noack, Caroline Ines Preuß, Kathleen Schwarz, Thomas Gitter, Peter Schrenk, Rupert Langer, Zsuzsanna Varga

Poster 7: The value of intraoperative frozen section examination in the survival of breast cancer

Zhu Anne Weihui, Kristina Tendl-Schulz, Mona Hirdler, Gerda Hofstetter, Eva-Maria Langthaler, Thomas Helbich, Daniela Kauer-Dorner, Ruth Exner, Rupert Bartsch, Christian F. Singer, Zsuzsanna Bago-Horvath, Ulrike M. Heber

Poster 8: PD-L1 and IRF1 expression is associated with improved therapy response in the prospective randomized neoadjuvant ABCSG 34 trial

Ulrike M. Heber, Dominik Hlauschek, Christian F. Singer, Daniel Egle, Richard Greil, Ruth Helfgott, Elisabeth Müller-Holzner†, Cornelia Hauser-Kronberger, Margaretha Rudas, Georg Pfeiler, Florian Fitzal, Sigurd Lax, Martin Filipits, Michael Gnant, Zsuzsanna Bago-Horvath

Poster 9: Pleuropulmonary blastoma: A rare childhood neoplasm with diverse histological subtypes

Fanni Hegedűs, Tamás Pancsa, Marianna Csenki, Lilla Györgyi Tiszlavicz, József Furák, Levente Kuthi, Tamás Zombori

Poster 10: Prognostic impact of the IASLC grading system of lung adenocarcinoma: a systematic review and meta-analysis

Fanni Hegedűs, Noémi Zombori-Tóth, Szabolcs Kiss, Tamás Lantos, Tamás Zombori

Poster 11: The role of methylation analysis in distinguishing cellular myxoma from low-grade myxofibrosarcoma

Hanna Henzinger, Iva Brčić, Jasminka Igrec, Theresa Marie Godschachner, Susanne Scheipl, Joanna Szkandera, Philipp Jurmeister, Bernadette Liegl-Atzwanger

Posters

Poster 12: Therapeutic and prognostic impact of new molecular-based classification of endometrial cancer. Our first experiences.

Hribikova Zuzana, Mateffy Stanislav, Benedek Barbara, Leskova Jaroslava, Straka Lubomir

Poster 13: High-Plex immunofluorescence analysis for immune cell typing and quantification of inflammatory lesions in kidney biopsies using digital image analysis – a pilot project

Johannes Kläger, Helga Schachner, Farsad Eskandary, Heinz Regele

Poster 14: A pilot study on dissecting the methylomes of diffuse large B-cell lymphomas of primary CNS and NOS types

Theo Kraus, Dorothee Hölzl, Karl Sotlar

Poster 15: Comparison of mTORC2 activity in primary and brain metastatic small cell lung carcinoma

Ildikó Krencz, Dániel Sztankovics, Fatime Szalai, Dorottya Moldvai, Judit Pápay, András Khoór, Anna Sebestyén

Poster 16: Clinical and Pathological Aspects of Epstein-Barr Virus-Positive Mucocutaneous Ulcer of Oral Gingiva: a Case Report

Nikolina Kurtović, Luka Klobučarić, Zlatka Radičević, Irena Zagorac, Branko Dmitrović

Poster 17: Methylome Profiling reveals loss of CDKN2A/B as a hallmark of RTK II Glioblastomas

Celina K. Langwieder, Karl Sotlar, Theo F. J. Kraus

Poster 18: Lymphangioma-like Kaposi Sarcoma: Unraveling Diagnostic Challenges and Differential Diagnosis a case report from our practice

Rinë Limani, Reshat Mati, Shkëlzen Reçica, Labinota Kondirolli, Brikenë Blakaj-Gashi, Drita Miftari Pazhari

Poster 19: Gastrointestinal MALT-Lymphoma surrounding an adenocarcinoma of the colon – long term side effect after an immune checkpoint inhibitor therapy of pulmonary squamous cell carcinoma?

Anja Marco, Reinhard Motz, Christine Beham-Schmid, Elmar Brehm, Gudrun Piringer, Rupert Langer

Poster 20: A Rarity among rarities: An extracavitary primary effusion lymphoma with unusual features in an unusual clinical setting

Michael Mayr, István Tajti, Andreas Chott

Poster 21: Preanalytical Standardization and Quality Assurance for Ki-67 in High-Risk Early Stage Breast Cancer

Petra Medac Corak

Poster 22: Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)

Maja L Nádorvári, József Tímár, István Kenessey, András Kiss, Tamás Barbai, Janina Kulka, Erzsébet Rásó

Posters

Poster 23: Acceleration of the technological process of the bone tissue decalcification using ultrasonic waves and modified decalcification solutions while maintaining the quality of the histomorphological image

Adam Nedoroščík, Alžbeta Blichárová, Ján Gajdoš, Rastislav Serbin, Marek Lacko

Poster 24: Choristoma like heterotopia in the rectum mimicking a malignant tumor

Nina Sigl, Alexander Ziachehabi, Claudia Grosse, Rupert Langer, Petar Noack

Poster 25: High-throughput digital spatial transcriptional profiling of upper tract urothelial carcinoma characterises grade- and stage- associated evolution and intra- and interpatient tumor heterogeneity

André Oszwald, Beatrice Donhauser, Theresa Hirschböck, Christopher Kaltenecker, David D Andrea, Eva Compérat

Poster 26: Complex analysis of 181 cases of extrapulmonary small cell carcinomas

Klára Pavlíčková, Jan Hojný, Petr Waldauf, Marián Švajdler, Pavel Dundr, Pavel Fabian, Iva, Staniczková Zambo, Nikola Hájková, Miroslava Flídrová, Jan Laco, Helena Hornychová, Patricie Delongová, Jozef Škarda, Radoslav Matěj

Poster 27: Rare mimick of the acute appendicitis – neuroma of the appendix

Zlatka Radičević, Nikolina Kurtović, Darija Alpeza, Luka Klobučarić, Adela Benkotić, Jasmina Rajc

Poster 28: Examination of non-conventional dysplasias besides colorectal adenocarcinoma in patients with inflammatory bowel disease – The first European pilot study

Szintia Almási, Bence Baráth, Panna Szaszák, Bence Péter Kővári, Anita Sejben

Poster 29: Colonic tubular adenoma with clear cell change – case report with whole exome sequencing

Ádám Ferenczi, Levente Kuthi, István Sejben, Anita Sejben

Poster 30: A Case of Infant Jaundice

Kristijan Skok, Benno Kohlmaier, Holger Till, Carolin Lackner, A. S. Knisely

Poster 31: Eosinophilic disorders behind middle lobe syndrome – two case reports

Dr. Zsófia Eszter Széll, Dr. Fanni Hegedűs, Dr. Kristóf Barath, Dr. Balázs Pécsy, Dr. Tibor Németh, Prof. Dr. László Tiszlavicz, Dr. Tamás Zombori

Poster 32: HER2-low status in invasive lobular carcinoma: A retrospective study at the Medical University of Vienna.

Kristina A. Tendl-Schulz, Ulrike M. Heber, Zaim Srndic, Elisabeth Gurnhofer, Mona Hirdler, Sabine Danzinger, Gerda Hofstetter, Eva-Maria Langthaler, Ruth Exner, Rupert Bartsch, Christian F. Singer, Zsuzsanna Bago-Horvath

Poster 33: Amebic colitis – a rare case presentation

Irena Veliki Dalić, Tamara Pikivača, Petra Jurešić, Lea Korša

Poster 34: Spatial transcriptomic analysis of hormone-naïve prostate cancer and matched lymph node metastases

Gabriel Wasinger, André Oszwald, Raheleh Sheibani, Eva Compérat, Gerda Egger

Poster 35: Newest Targeted Biological Therapies at Törökbálint Pulmonology Hospital

Kamel Yahya

Poster 36: Combining three-dimensional histopathology with bread loafing and orientation without artificial coloring

Nina Zila, Philipp Tschandl

Poster 37: Proposal of a grading system for squamous cell carcinoma of the lung – the prognostic importance of tumour budding, single cell invasion, and nuclear diameter

Noémi Zombori-Tóth, Fanni Hegedűs, Szintia Almási, Anita Sejben, László Tiszlavicz, József Furák, Gábor Cserni, Tamás Zombori

Poster 38: Morphological Changes in the Brain in Different Periods of Ischemic Stroke

Ruslana I. Falion, Yuriy O. Pospishil, Yuliya I. Beketova

Poster 39: The spectrum of positive immunohistochemical markers in ALK-negative anaplastic lymphomas and possible resulting interpretational errors

Michael Mayr, Andreas Chott

Poster 40: Virtual Microscopy for Academic Pathology Education at the Medical University of Vienna

Maximilian C. Köller, Ana-Iris Schiefer, Christopher Kaltenecker, Maximilian Gletthofer, Renate Kain

Poster 41: SWI/SNF Complex Subunits and Mismatch-Repair Proteins in Colorectal Carcinomas

Bračič Tomažič S., Setaffy L., Lax S.F.

Poster 42: Comparative Molecular Analysis of Non-Small Cell Lung Carcinoma by Idylla and Next Generation Sequencing

Scheiber O., Jost M., Kashofer K., Brcic L., Lax S.F.

Poster 43: The single case papillary craniopharyngioma in an adult

Stypynets L., Panasiuk I., Zhytynska H., Vovk V., Falion R.



September 26th – 28th 2024

Altes Hallenbad & Stella Vorarlberg, Feldkirch (AT)

Joint Annual Meeting of SGPath and ÖGPath 2024

www.oegpath.at




SGPath | SSPath

SOCIÉTÉ SUISSE DE PATHOLOGIE
SCHWEIZERISCHE GESELLSCHAFT FÜR PATHOLOGIE
SWISS SOCIETY OF PATHOLOGY



Venue and Transport Information



TechGate Vienna

Wissenschafts- und Technologiepark GmbH, Donau-City-Straße 1, 1220 Wien

Public Transport

Metro U1 (red line)

Please take the stop „Kaisermühlen – Vienna International Center“ and exit in the direction of „Schütttaustraße/Donau-City-Straße“. From there it is an approx. 2-minutes walk

Bus

The following bus lines stop right next to the venue:
20A, 92A, 92B, Airport Bus, N90

Car / Parking

Departure from the Reichsbrücke, coming from the city center at the first roundabout on the left, exit towards Donau-City-Straße. The entrance to the parking garage is immediately after the turnoff from the 2nd roundabout. You can get a reduced parking ticket at the registration desk.

ATTENTION:

The reduced parking ticket is only valid in the in-house TechGate Garage

Sponsors

Gold-Sponsor



Silber-Sponsor



Industry Symposia




Exhibitors and Advertisers



uPath HER2 Dual ISH Bildanalyse (Mamma)


Gebrauchsfertige Reagenzien, schneller, einheitlicher
und automatisierter Algorithmus



VENTANA® HER2 Dual ISH DNA Probe Cocktail Assay
Vollautomatisierte Färbung



VENTANA® DP 600 Slide Scanner
Hochwertige Bilder mit präzisen, schnellen und
benutzerfreundlichen Scannern



uPath enterprise software
Die Pathologie-Software bietet einen nahtlosen
Workflow für die Befundung




Image analysis
Algorithmen-unterstützte Bestimmung des
HER2-Genstatus